Compare IT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IT | GH |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 13.3B |
| IPO Year | 2010 | 2018 |
| Metric | IT | GH |
|---|---|---|
| Price | $164.16 | $85.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 20 |
| Target Price | ★ $270.44 | $117.80 |
| AVG Volume (30 Days) | 1.4M | ★ 1.6M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 9.65 | N/A |
| Revenue | ★ $2,021,441,000.00 | $982,021,000.00 |
| Revenue This Year | $3.66 | $33.40 |
| Revenue Next Year | $5.15 | $28.32 |
| P/E Ratio | $16.69 | ★ N/A |
| Revenue Growth | 13.30 | ★ 32.88 |
| 52 Week Low | $139.18 | $36.36 |
| 52 Week High | $451.73 | $120.74 |
| Indicator | IT | GH |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 35.88 |
| Support Level | $155.50 | $82.26 |
| Resistance Level | $172.23 | $103.16 |
| Average True Range (ATR) | 6.32 | 3.68 |
| MACD | 1.79 | 0.09 |
| Stochastic Oscillator | 55.49 | 23.00 |
Gartner Inc delivers actionable, objective business and technology insights that drive smarter decisions and stronger performance on an organization's mission-critical priorities. It delivers its products and services globally through three reportable segments - Business and Technology Insights, Conferences and Consulting. Insights equips executives and their teams from every Majority function, geography, industry and sector with actionable, objective insights, guidance and tools. Conferences provides executives and teams across an organization the opportunity to learn, share and network. and Consulting serves senior executives technology-driven strategic initiatives leveraging the power of Gartner's actionable, objective insight. The Majority revenue is derived from the Insights segment.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.